Zydus Lifesciences announced that it has got approval from the US Food and medicine Administration to offer a generic medicine used to treat specific stomach and esophageal issues. According to a statement from the medicine maker, the business has gained permission from the US Food and medicine Administration (USFDA) to market Esomeprazole Magnesium for delayed-release oral solution in 20 mg and 40 mg doses in the American market. Esomeprazole is a medication used to treat stomach and esophageal issues such as acid reflux and ulcers.
It works by decreasing the amount of acid produced by the stomach and alleviating symptoms such as heartburn, difficulty swallowing, and coughing. This drug aids in the healing of acid damage to the stomach and oesophagus, the prevention of ulcers, and the prevention of esophageal cancer. According to Zydus Lifesciences, the product would be made at the group's formulation manufacturing facility in Moraiya, Ahmedabad. According to IQVIA MAT April 2023 statistics, Esomeprazole Magnesium for Delayed-Release Oral Suspension (20 mg and 40 mg) has yearly sales in the United States of USD 42 million. Zydus Lifesciences shares closed 0.16 percent down on the BSE at Rs 514.20 per share.
, CDSCO.jpg)
.jpg)